LEO Pharma A/S

Kymera Therapeutics delivered a big win with first-in-human data for an oral STAT6 degrader, a potential new class of medicine for allergic diseases. STAT6 is a key signaling node on the IL-4/IL-13 pa

Leo Pharma has posted a strong set of financials for the first quarter of 2025, “building on build on the momentum that we delivered in 2024,” CEO Christophe Bourdon has told Scrip . Revenues rose by

A decade ago, Almirall took the strategic decision to focus exclusively on medical dermatology, and after posting a strong set of financials for 2024, CEO Carlos Gallardo has told investors that “I’m

Leo Pharma has posted a strong set of financials for 2024, a year which saw the Danish drugmaker nail its three ambitions of increasing top-line growth, improving profitability and advancing in innova